NEWPORT BEACH, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) — Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of management will be participating in two investment conferences in September.
| Event: | H.C. Wainwright 23rd Annual Global Investment Conference |
| Date: | Monday, September 13, 2021 |
| Time: | Available on-demand starting at 7:00am ET |
| Event: | Cantor 2021 Virtual Global Healthcare Conference |
| Date: | Tuesday, September 28, 2021 |
| Time: | 3:20pm ET |
Audio webcasts of these events will be available on the investor relations section of Evolus’ website at www.evolus.com. Replays of the webcasts will be available for 90 days after the date of each presentation.
About Evolus, Inc.
Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. Approved in 2019 by the U.S. Food and Drug Administration, Jeuveau® (prabotulinumtoxinA-xvfs) is the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau® is powered by Evolus’ unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. Visit us at www.evolus.com.
Jeuveau® is a registered trademark of Evolus, Inc.
Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.
Evolus, Inc. Contacts:
Investor Contact:
David K. Erickson, Evolus, Inc.
Vice President, Investor Relations
Tel: 949-966-1798
Email: david.erickson@evolus.com
Media Contact:
Crystal Muilenburg, Evolus, Inc.
Chief Marketing Officer
Tel: 949-284-4506
Email: media@evolus.com
- HRZN Originates $33.5 Million of New Loans in Q1 - - HRZN Ends Quarter…
athenahealth’s cloud-based suite of EHR, RCM, and patient engagement solutions empowers ZoomCare to scale and…
Cedars-Sinai Connect Expands Virtual Healthcare Services After Initial Success Treating Thousands of California AdultsLOS ANGELES--(BUSINESS…
Enhanced AI and analytics capabilities will help ACOs meet eCQM guidelines and navigate the changes…
The Food and Drug Administration approves CAR T-Cell therapy Abecma as a second-line treatment and…
UPPSALA, SWEDEN / ACCESSWIRE / April 10, 2024 / Senzime (STO:SEZI)(OTCQX:SNZZF), an industry leader in…